Feasibility Study to Evaluate the Role of a Novel Device in Childbirth
Launched by THE ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST · May 12, 2022
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new device designed to help prevent a serious problem that can occur during childbirth: the accidental leaving behind of surgical items, like swabs, inside a patient's body. This issue, known as a "never event," can lead to significant complications and even life-threatening situations for patients. The trial aims to see if this device can help healthcare providers keep track of swabs used during childbirth, which is particularly important during procedures like Cesarean sections or repairs after vaginal births.
To participate in this study, women aged 18 and older who are receiving care from midwives or consultants and are willing to consent to the trial may be eligible. However, those with certain medical conditions or who are experiencing emergencies during childbirth may not be included. Participants can expect to use the new device during their delivery, and the study will help researchers determine if it effectively reduces the risk of surgical items being left behind. This trial is an important step in improving patient safety during childbirth and ensuring better outcomes for mothers and babies.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Midwifery lead and consultant lead patient older than 18 years.
- • Consented to participation after an informed choice.
- Exclusion Criteria:
- • • Under 18 years of age
- Antenatal (before labour):
- * Patients who have a high risk of expected/unexpected maternal, fetal or neonatal deterioration such that during birth, the focus of attention would be towards safe patient care and observation required for using the swab-counter device system would not be possible such as :
- • Patients who are seriously unwell and require high dependency care.
- • Maternal cardiac conditions
- • Severe pre-eclampsia
- • Fetal anomalies where neonatal deterioration is expected (These will be relatively rare conditions where the doctor/midwife would decide to not recruit the patient)
- Intrapartum and postpartum factors:
- • Patient having an emergency Caesarean section instead of a vaginal birth due to maternal or fetal indication.
- • Eclampsia (seizure/fitting in labour or after delivery)
- • Maternal cardiac conditions requiring high dependency care
- • Severe sepsis requiring high dependency care
- • Fetal anomalies where neonatal deterioration is expected
About The Royal Wolverhampton Hospitals Nhs Trust
The Royal Wolverhampton Hospitals NHS Trust is a leading healthcare provider in the West Midlands, dedicated to delivering high-quality patient care and advancing medical research through clinical trials. As a prominent NHS trust, it encompasses a range of specialized services across multiple hospitals, focusing on innovation and evidence-based practices. The Trust actively engages in clinical research to enhance treatment options and improve patient outcomes, fostering collaboration among healthcare professionals, researchers, and academic institutions. Committed to patient safety and ethical standards, the Royal Wolverhampton Hospitals NHS Trust plays a pivotal role in advancing healthcare through rigorous clinical trials and research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Aditi Desai
Principal Investigator
The Royal Wolverhampton NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials